Shares of Natco Pharma Ltd gained up to 4.1% after the company, along with partner Breckenridge Pharmaceutical, launched Pomalidomide Capsules in the US, a generic version of Pomalyst. The drug treats multiple myeloma and Kaposi sarcoma, comes in 1mg–4mg strengths, and targets a $3.2 billion market opportunity.